<< Back To Search

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
We are testing a new drug called SAR442257 to see how much patients with relapsed and refractory multiple myeloma and non-Hodgkin lymphoma can handle. We want to find the safe amount of the drug for future testing. We also want to check if the drug is safe and if it works against the cancer.
*Third Opinion AI Generated Synopsis

Trial Summary
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the pharmacokinetics (PK) profile of SAR442257 To evaluate the potential immunogenicity of SAR442257 To assess preliminary evidence of antitumor activity

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: